GlassScriptPhysician profile
Dauda M Rogers
NPI 1750949798
$3,997.16
in general payments reported to CMS, 2019-2025
19 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $81.39 · 2023: $1,079 · 2024: $1,524 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,915.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,668.98 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $444.67 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $425.00 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $322.21 | 2023-2025 | |
| Exact Sciences Corporation | $279.57 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $276.89 | 2023-2025 | Vraylar, Qulipta |
| Amgen INC. | $100.16 | 2024-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $97.80 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $72.57 | 2024 | |
| Lundbeck LLC | $69.82 | 2024-2025 | Vyepti |
| Idorsia Pharmaceuticals US INC | $64.89 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $33.68 | 2024 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.06 | 2024-2025 | Xifaxan |
| Insulet Corporation | $27.62 | 2025 | Omnipod |
| Astellas Pharma US INC | $18.80 | 2024 | Veozah |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $16.15 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $15.37 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.00 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $14.92 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dauda Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.